CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 36 enrolled
Drug / intervention
Eicosapentaenoic Aciddrug
Likely dose
Eicosapentaenoic Acid 4 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00815685
NCT00815685N/ACompleted
CompareCT.gov

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Dec 30, 2008·Updated Mar 23, 2017

In Brief

A clinical study evaluating Eicosapentaenoic Acid for Cancer Cachexia. Completed, enrolled 36 participants across 2 sites.

Detailed Summary

The data collected through this pilot study will allow us to increase our understanding of cancer cachexia and the effect of Eicosapentaenoic Acid (EPA) on cancer cachexia. Our long-term goal is to improve nutritional treatment and reduce illness in the cancer patient population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer Cachexia
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 30, 2008
Enrollment StartJul 1, 2007
Primary CompletionMar 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.5 years ago

Interventions

Eicosapentaenoic Aciddrug

Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.